Risk factors for ganciclovir-induced thrombocytopenia and leukopenia

Kazuaki Matsumoto, Akari Shigemi, Kazuro Ikawa, Naoko Kanazawa, Yuko Fujisaki, Norifumi Morikawa, Yasuo Takeda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Ganciclovir is a nucleoside guanosine analogue that exhibits therapeutic activity against human cytomegalovirus infection, and is primarily excreted via glomerular filtration and active tubular secretion. The adverse effects induced by ganciclovir therapy are generally of a hematological nature and include thrombocytopenia and leukopenia. Low marrow cellularity and elevated serum creatinine have been identified as risk factors for ganciclovir-induced neutropenia. However, the risk factors for thrombocytopenia have yet to be determined. Therefore, this study investigated patients administered ganciclovir to determine the risk factors for thrombocytopenia and leukopenia. Thrombocytopenia occurred in 41 of these patients (30.6%). Multivariate logistic regression analysis identified three independent risk factors for thrombocytopenia: cancer chemotherapy (odds ratio (OR)=3.1), creatinine clearance (3) (OR=3.7) and the ganciclovir dose (≥12 mg/kg/d) (OR=7.8) were identified as risk factors. These results demonstrated that several factors influenced the occurrence of ganciclovir-induced thrombocytopenia and leukopenia, and suggest that special attention should be paid to patients receiving cancer chemotherapy with a low creatinine clearance (

Original languageEnglish
Pages (from-to)235-238
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume38
Issue number2
Publication statusPublished - 2015 Feb 1
Externally publishedYes

    Fingerprint

Keywords

  • Ganciclovir
  • Leukopenia
  • Thrombocytopenia

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Matsumoto, K., Shigemi, A., Ikawa, K., Kanazawa, N., Fujisaki, Y., Morikawa, N., & Takeda, Y. (2015). Risk factors for ganciclovir-induced thrombocytopenia and leukopenia. Biological and Pharmaceutical Bulletin, 38(2), 235-238.